<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01133080</url>
  </required_header>
  <id_info>
    <org_study_id>SHA-0008-10</org_study_id>
    <nct_id>NCT01133080</nct_id>
  </id_info>
  <brief_title>Minocycline as an Adjunctive Therapy for Schizophrenia: a Randomized Controlled Study</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shalvata Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shalvata Mental Health Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Double - Blind, Randomized, single centered study. The purpose of this study is to assess the
      feasibility of minocycline vs. placebo, added to atypical antipsychotic medications, for
      positive symptoms in adults suffering from schizophrenia.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2010</start_date>
  <completion_date type="Anticipated">January 2013</completion_date>
  <primary_completion_date type="Anticipated">January 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Positive symptoms</measure>
    <time_frame>from baseline to the end of the study (day 56)</time_frame>
    <description>Positive symptoms: The change in Scale for the Positive and Negative Syndrome Scale (PANSS) score from baseline to the end of the study and the change in Clinical Global Impression Scale (CGI).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Minocycline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Minocycline</intervention_name>
    <description>minocycline 200 mg/day orally in two divided doses for the second week. From weeks 3 to weeks 5, minocycline 400 mg/day orally in two divided doses.</description>
    <arm_group_label>Minocycline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo 200 mg/day orally in two divided doses for the first week. placebo 200 mg/day orally in two divided doses for the second week.
From weeks 3 to weeks 5, placebo 400 mg/day orally in two divided doses.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women 20-65 years of age.

          -  Primary DSM-IV diagnosis of Schizophrenia based on SCID for schizophrenia and
             confirmed by two senior psychiatrists.

          -  Patients who scored &quot;moderate&quot; (4) or higher on at least three of seven positive items
             in PANSS

          -  Initiated on treatment with atypical anti-psychotic medication.

          -  Capable and willing to provide informed consent

          -  Able to adhere to the treatment schedule

          -  Able to read, hear, write and speak the local language.

          -  Has signed a written informed consent to participate in the study

        Exclusion Criteria:

          -  Patients with acute, unstable, significant, or untreated medical illness besides
             schizophrenia including alcohol and drug dependence, or depression.

          -  Current suicidal ideation or history of a suicide attempt in the past 3 years

          -  Known or suspected pregnancy or women of childbearing potential and not using a
             medically accepted form of contraception when engaging in sexual intercourse. or women
             who are breastfeeding

          -  Subjects who were taking a known contraindication to minocycline treatment.

          -  Subjects who had received treatment with minocycline or Î²-lactam antibiotics in the
             preceding half year before study entry.

          -  Subjects who were under compulsory hospitalization.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yechiel Levkovitz, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shalvata MHC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>yechiel levkovitz, MD, PhD</last_name>
    <phone>972-9-7478644</phone>
    <email>levkovit@netvision.net.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shalvata Mental Health Center</name>
      <address>
        <city>Hod Hasharon</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hilik Levkovitz, prof.</last_name>
      <phone>972-9-7478644</phone>
      <email>ylevk@clalit.org.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>shalvata MHC</name>
      <address>
        <city>Hod HAsharon</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>yechiel levkovitz</last_name>
      <phone>972-9-7478644</phone>
    </contact>
    <investigator>
      <last_name>yechiel levkovitz, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2010</study_first_submitted>
  <study_first_submitted_qc>May 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2010</study_first_posted>
  <last_update_submitted>January 4, 2012</last_update_submitted>
  <last_update_submitted_qc>January 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Minocycline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

